Gadolinium (Gd) based contrast agents (GBCA) are widely used in magnetic resonance imaging (MRI) and are paramount to cancer diagnostics. In this context, accurate quantification of Gd in blood and/or plasma (biological media) is essential to tumor pharmacokinetic analysis, and current methods for doing so are both low throughput and clinically unavailable. Here, we have demonstrated the use of a sensitized GBCA, Gd[DTPA-cs124], to measure the concentration of Gd in biological media via luminescence quantification following transmetallation with a terbium (Tb) salt. As such, our assay provides a straightforward and high throughput method of measuring Gd in biological media using a standard laboratory plate reader. Furthermore, we report both increased stability and relaxivity for Gd[DTPA-cs124], as well as its efficacy as an MRI contrast agent when compared to its clinically approved analog, Magnevist. Our results indicate that similar chemical modification to existing clinically approved GBCA may likewise yield favorable property changes, with the added ability to quantify Gd.

Rapid quantification of gadolinium: Transmetallation assay for measurements in blood and plasma

Where thousands of chemistry professionals meet to share ideas and advance scientific and technical knowledge. Spring 2023 abstracts, posters, and presentations will launch at the end of March.

ACS Spring 2023

The official archive and repository for all ACS Meetings & Expositions abstracts and select posters or presentations.